Aesthetic device rankings, from public records
Updated Jul 26, 2026
Proxy signals from openFDA, PubMed and ClinicalTrials.gov.
Nothing here ranks how well a treatment works: 510(k) devices are cleared, not approved. What this measuresEvery ranking on this page is a proxy built from public records: FDA 510(k) decisions, PubMed publication counts and ClinicalTrials.gov registrations. A 510(k) clearance means FDA agreed a device is substantially equivalent to one already on the market — it is not an approval and not a finding of effectiveness. Devices cleared through PMA, and drugs through BLA or NDA, are approved, and the pathway is named wherever a product appears. No adverse-event data is published anywhere on this site.
Methodology →
papers per year · 2016–2026 · 2026 partial
Papers a year rose 120% between 2016 and 2025, from 813 to 1,786; Injectables added the most (up 493 papers) and Body Contouring the least (up 59).
Values and shares are 2025, the latest full year.
| Lasers & Light | Injectables | Body Contouring | Skin & Topicals | RF & Microneedling | Total | |
|---|---|---|---|---|---|---|
| 2016 | 337 | 164 | 72 | 179 | 61 | 813 |
| 2017 | 307 | 182 | 63 | 173 | 55 | 780 |
| 2018 | 334 | 200 | 70 | 154 | 67 | 825 |
| 2019 | 343 | 219 | 63 | 193 | 92 | 910 |
| 2020 | 403 | 314 | 81 | 211 | 115 | 1,124 |
| 2021 | 447 | 309 | 84 | 239 | 134 | 1,213 |
| 2022 | 404 | 320 | 91 | 227 | 154 | 1,196 |
| 2023 | 360 | 359 | 122 | 232 | 129 | 1,202 |
| 2024 | 398 | 499 | 97 | 266 | 173 | 1,433 |
| 2025 | 503 | 657 | 131 | 269 | 226 | 1,786 |
| 2026 | 311 | 431 | 47 | 190 | 149 | 1,128 |
PubMed records per year matching our fixed treatment queries — publication volume, not quality, efficacy or market share. What this measuresNumber of PubMed records matching each modality's fixed, hand-written title/abstract query, windowed to a single publication year. It measures publication volume about a TECHNIQUE, not a brand. It is NOT a quality score, NOT an efficacy measure, and NOT a count of randomised trials. 2026 is a partial year (run date 2026-07-26); its bar is short because the year is short, not because interest fell. 2026 contains only papers indexed by the run date (2026-07-26). Render it visually distinct (e.g. hollow/hatched) or annotate it; never let it read as a decline. The 25 modality series are summed into the five site categories; every per-modality number and query is on the Studies page.
Methodology →
clearances per year · 2015–2026 · 2026 partial
510(k) decisions a year rose 82% between 2015 and 2025, from 140 to 255; Lasers & Light added the most (up 100 clearances) and Body Contouring the least (up 4).
Values and shares are 2025, the latest full year.
| Lasers & Light | Body Contouring | Skin & Topicals | RF & Microneedling | Total | |
|---|---|---|---|---|---|
| 2015 | 68 | 17 | 0 | 55 | 140 |
| 2016 | 77 | 14 | 0 | 72 | 163 |
| 2017 | 93 | 17 | 0 | 59 | 169 |
| 2018 | 90 | 9 | 0 | 52 | 151 |
| 2019 | 67 | 21 | 0 | 58 | 146 |
| 2020 | 70 | 17 | 0 | 69 | 156 |
| 2021 | 89 | 18 | 1 | 58 | 166 |
| 2022 | 123 | 12 | 0 | 66 | 201 |
| 2023 | 114 | 25 | 0 | 79 | 218 |
| 2024 | 141 | 17 | 0 | 71 | 229 |
| 2025 | 168 | 21 | 0 | 66 | 255 |
| 2026 | 63 | 7 | 0 | 40 | 110 |
Injectables & topicals reach market via PMAPMAPremarket approval: the FDA's most demanding device review, in which the company has to hand over its own clinical evidence that the device is safe and does what it claims., BLABLABiologics licence application: the route used for products grown or purified from living sources, such as botulinum toxins. or NDANDANew drug application: the route used for a new drug, including injectable products regulated as drugs rather than as devices. approval, not 510(k)510(k)A submission in which a company shows the FDA that its device works much like a device already legally on sale, so the company does not have to prove the whole thing over from scratch. clearance — they do not appear in this feed.
510(k) clearance decisions per year in the tracked codes — filing activity, not sales or clinical benefit. What this measuresCount of FDA 510(k) clearance decisions per year whose product code is in each Dalphene category group. Not approvals, not efficacy, not safety, not sales — filing activity only. Category groups include broad-mixed codes (GEX in lasers-light, GEI in rf-microneedling, NGX in body-contouring), so these yearly totals carry non-aesthetic devices too; the per-code split is not fetched per year. 2026 is a partial year through the run date. Unlike the monthly series, these are count queries — there is no narrow-only variant here because a per-breadth split would double the request count. Charts using this series must carry the broad-mixed caveat on the chart. 2026 covers 01-01 through the run date (2026-07-26) only. No injectables group exists: neuromodulators (BLA) and fillers (PMA) are not 510(k) records. Absence is structural, not a gap.
Methodology →
Each card: the FDA decision date, the device name as the record spells it, then the applicant and category. The mono-spaced pill is the K-numberK-numberThe reference the FDA stamps on a 510(k) submission, written like K123456, which is how you pull up the exact record for a device. of that 510(k) — cleared, not approved — and it opens the record on openFDAopenFDAThe FDA's own public data service, which is where every clearance record on this site comes from..
- Jul 10, 2026Capenergy C Equipments RF C200 and C400 DrakarianCapenergy Medical S.L.
- Jul 1, 2026ChromixTermosalud S.L.
- Jun 29, 2026LED Light Therapy Masks (LED Face Mask Pro FAC08NA, LED Chest Mask Pro FAC09NA)Guangdong Newdermo Biotech Co., Ltd.
- Jun 26, 2026Laser Hair Growth Devices (HR-H1, HR-H2, HR-H3, HR-H4, HR-H5, HR-H6, HR-H7, HR-H8, HR-H9, HR-H10, HR-I1, HR-I2, HR-I3, HR-I4, HR-I5)Ziree Co., Ltd.
No rows in this category.
The newest 510(k) decisions in unambiguously aesthetic codes — 4 cards because there were 4. What this measuresCount of FDA 510(k) clearance decisions whose product code is on the Dalphene aesthetic allowlist. A clearance means FDA agreed the device is substantially equivalent to a legally marketed predicate. It is NOT an approval, NOT a measure of efficacy, NOT a measure of safety, and NOT a measure of sales. Manufacturers file multiple 510(k)s for the same platform (new applicators, new indications, new software), so clearance counts track filing activity, not the number of distinct products. This strip shows only narrow-code decisions from the last 30 days — 4 cards because exactly 4 decisions qualified; the strip is never padded. 3 further decisions in the same 30 days came from the broad codes (GEX, GEI, NGX, which also carry non-aesthetic devices) and appear in the full feed below, tagged.
Methodology →
Each card draws PubMedPubMedThe United States National Library of Medicine's index of published medical literature, which is where this site's paper counts come from. records a year for one treatment, 2016 to 2026. The large figure is 2025, the last full year; the pill beside it is the change against 2024. The final point of every line is the partial current year and is drawn hollow.
| Botulinum toxin (cosmetic) | |
|---|---|
| 2016 | 87 |
| 2017 | 86 |
| 2018 | 87 |
| 2019 | 105 |
| 2020 | 137 |
| 2021 | 129 |
| 2022 | 140 |
| 2023 | 151 |
| 2024 | 206 |
| 2025 | 258 |
| 2026 | 177 |
| Hyaluronic acid filler | |
|---|---|
| 2016 | 44 |
| 2017 | 55 |
| 2018 | 64 |
| 2019 | 80 |
| 2020 | 110 |
| 2021 | 119 |
| 2022 | 114 |
| 2023 | 128 |
| 2024 | 164 |
| 2025 | 196 |
| 2026 | 120 |
| Topical retinoid | |
|---|---|
| 2016 | 121 |
| 2017 | 121 |
| 2018 | 110 |
| 2019 | 127 |
| 2020 | 141 |
| 2021 | 155 |
| 2022 | 138 |
| 2023 | 150 |
| 2024 | 162 |
| 2025 | 169 |
| 2026 | 110 |
| Ablative / hybrid fractional laser | |
|---|---|
| 2016 | 100 |
| 2017 | 82 |
| 2018 | 80 |
| 2019 | 100 |
| 2020 | 118 |
| 2021 | 141 |
| 2022 | 111 |
| 2023 | 84 |
| 2024 | 94 |
| 2025 | 134 |
| 2026 | 83 |
| Mechanical microneedling | |
|---|---|
| 2016 | 17 |
| 2017 | 25 |
| 2018 | 29 |
| 2019 | 47 |
| 2020 | 57 |
| 2021 | 61 |
| 2022 | 69 |
| 2023 | 74 |
| 2024 | 92 |
| 2025 | 119 |
| 2026 | 75 |
| Non-ablative fractional laser | |
|---|---|
| 2016 | 90 |
| 2017 | 73 |
| 2018 | 82 |
| 2019 | 78 |
| 2020 | 90 |
| 2021 | 83 |
| 2022 | 93 |
| 2023 | 66 |
| 2024 | 82 |
| 2025 | 111 |
| 2026 | 54 |
| Poly-L-lactic acid collagen stimulator | |
|---|---|
| 2016 | 13 |
| 2017 | 18 |
| 2018 | 15 |
| 2019 | 15 |
| 2020 | 32 |
| 2021 | 32 |
| 2022 | 27 |
| 2023 | 35 |
| 2024 | 65 |
| 2025 | 109 |
| 2026 | 76 |
| Calcium hydroxylapatite filler | |
|---|---|
| 2016 | 20 |
| 2017 | 23 |
| 2018 | 34 |
| 2019 | 19 |
| 2020 | 35 |
| 2021 | 29 |
| 2022 | 39 |
| 2023 | 45 |
| 2024 | 64 |
| 2025 | 94 |
| 2026 | 58 |
| Pulsed dye laser | |
|---|---|
| 2016 | 55 |
| 2017 | 63 |
| 2018 | 67 |
| 2019 | 54 |
| 2020 | 61 |
| 2021 | 83 |
| 2022 | 68 |
| 2023 | 62 |
| 2024 | 78 |
| 2025 | 88 |
| 2026 | 46 |
| Topical hydroquinone / triple combination | |
|---|---|
| 2016 | 46 |
| 2017 | 36 |
| 2018 | 29 |
| 2019 | 44 |
| 2020 | 51 |
| 2021 | 60 |
| 2022 | 69 |
| 2023 | 56 |
| 2024 | 70 |
| 2025 | 70 |
| 2026 | 58 |
No rows in this category.
PubMed papers per year per treatment; deltas are 2025 vs 2024 on the stated base. What this measuresNumber of PubMed records matching each modality's fixed, hand-written title/abstract query, windowed to a single publication year. It measures publication volume about a TECHNIQUE, not a brand. It is NOT a quality score, NOT an efficacy measure, and NOT a count of randomised trials. 2026 is a partial year (run date 2026-07-26); its bar is short because the year is short, not because interest fell. 2026 contains only papers indexed by the run date (2026-07-26). Render it visually distinct (e.g. hollow/hatched) or annotate it; never let it read as a decline. The ten multiples share one 0-based scale so band heights are comparable. Delta chips compare the two latest FULL years (2025 vs 2024); young or small modalities swing harder on small bases — the base count is in each chip's tooltip. All 25 modality series are in this section's data table.
Methodology →
Four separate facts about the registered literature — who paid, how many humans, what came back, how concentrated. None of them is a score. What this measuresNone of these numbers rank treatments. A modality can have 90% industry-sponsored studies and excellent evidence, or 90% independent studies and thin evidence. Sponsor mix, enrollment size and results posting are three separate facts about the registered literature; they are inputs to a conversation with a clinician, not a score, and nothing here speaks to safety. Every number on this page is computed from the same version-pinned ClinicalTrials.gov queries the study counts elsewhere on the site use, re-fetched on 2026-07-26; the recomputed totals matched the published study counts exactly for all 25 modalities, so the two layers describe the same set of studies. 2 of the 25 tracked modalities returned a genuine fetched zero on this query (Non-invasive laser lipolysis, RF body contouring): nothing is drawn for them, because there is nothing to draw, not because a number went missing.
Methodology →
Independent vs industry-funded trials
Each column is one modality; each band is the lead-sponsor classSponsor classThe registry's grouping of who ran a study — a company, the national health agency, another government body, or the catch-all bucket that holds hospitals and universities. the registry recorded, and the colours here are sponsor classes, not site categories.
Axis labels are shortened names. Terms in them: Dermal fillerDermal fillerAn injected gel that adds volume under the skin. · NeuromodulatorNeuromodulatorAn injected product that temporarily relaxes a muscle, which is the category botulinum toxin products sit in. · RFRFRadiofrequency: energy that heats tissue from the inside by passing an electrical current through it rather than by shining light on it. · BBLBBLBroadband light: one manufacturer's name for its intense pulsed light platform.
Lead-sponsor class of every registered study, by modality
share of each modality's registered studies
University, hospital or other accounts for 86–92% of registered trials for Pulsed dye laser, Ablative / hybrid fractional laser and Non-ablative fractional laser, and 15–23% for Hyaluronic acid filler and Botulinum toxin (cosmetic).
Other combines 5 series each under 3% of the total: NIH, Other US federal agency, Other government, Research network and Individual. Each keeps its own colour in the chart and its own row in the data table.
| Industry | NIH | Other US federal agency | Other government | Research network | Individual | University, hospital or other | Total | |
|---|---|---|---|---|---|---|---|---|
| Hyaluronic | 81 | 0 | 0 | 0 | 4 | 0 | 15 | 100 |
| Botulinum | 75 | 0 | 0 | 1 | 1 | 0 | 23 | 100 |
| RF needling | 54 | 0 | 0 | 0 | 0 | 0 | 46 | 100 |
| Retinoid | 47 | 1 | 0 | 2 | 1 | 1 | 48 | 100 |
| Broadband | 37 | 0 | 0 | 3 | 2 | 0 | 58 | 100 |
| Hydroquinone | 35 | 0 | 0 | 4 | 2 | 0 | 59 | 100 |
| Microneedling | 18 | 0 | 1 | 6 | 0 | 0 | 75 | 100 |
| Non-ablative | 12 | 0 | 0 | 1 | 1 | 0 | 86 | 100 |
| Ablative | 11 | 0 | 0 | 2 | 1 | 0 | 86 | 100 |
| Pulsed dye | 8 | 0 | 0 | 0 | 0 | 0 | 92 | 100 |
Lead sponsor only. A trial run by a university on a manufacturer's grant is classed by its registered lead sponsor, and the registry does not publish the funding behind it.
Industry funding is not evidence of bad science — this measures who registered and paid for the trials, nothing else. What this measuresShare of studies whose lead sponsor is classed INDUSTRY by the registry, out of studies with a known sponsor class; it tells you who FUNDED and ran the trial, and nothing else -- industry funding is not evidence of bad science, large industry RCTs are often the most rigorous work in aesthetics, and an independent 12-patient case series is not automatically better than a 300-patient manufacturer trial. Registry-assigned lead-sponsor class for every fetched study (INDUSTRY, NIH, OTHER_GOV, OTHER, NETWORK, INDIV); it describes the funding mix of the registered literature, not its quality, and 'OTHER' is mostly universities and hospitals rather than a meaningful third category -- studies with no class recorded are counted as unknown, never guessed. The ten columns are the ten modalities with the most registered studies, ordered by industry share; every modality is on the see-more page. Bars are whole percentage points and sum to 100 by largest remainder, so a class holding less than half a point of a column rounds to zero and its band disappears — the underlying counts are in this figure's data table. Across all 23 modalities 562 of 1,467 studies with a known lead-sponsor class were industry-led. The category chips filter the ranked lists on this page; this figure always shows the same ten modalities, and its colours are sponsor classes, not categories.
Methodology →
| Modality | Registered studies | Industry | NIH | Other US federal agency | Other government | Research network | Individual | University, hospital or other |
|---|---|---|---|---|---|---|---|---|
| Hyaluronic acid filler | 46 | 37 | 0 | 0 | 0 | 2 | 0 | 7 |
| Botulinum toxin (cosmetic) | 186 | 139 | 0 | 0 | 2 | 2 | 0 | 43 |
| Radiofrequency microneedling | 37 | 20 | 0 | 0 | 0 | 0 | 0 | 17 |
| Topical retinoid | 343 | 163 | 2 | 1 | 8 | 2 | 2 | 165 |
| IPL / broadband light | 43 | 16 | 0 | 0 | 1 | 1 | 0 | 25 |
| Topical hydroquinone / triple combination | 51 | 18 | 0 | 0 | 2 | 1 | 0 | 30 |
| Mechanical microneedling | 135 | 24 | 0 | 1 | 9 | 0 | 0 | 101 |
| Non-ablative fractional laser | 128 | 15 | 0 | 0 | 1 | 1 | 0 | 111 |
| Ablative / hybrid fractional laser | 229 | 24 | 0 | 1 | 5 | 2 | 0 | 197 |
| Pulsed dye laser | 72 | 6 | 0 | 0 | 0 | 0 | 0 | 66 |
Humans actually tested
Under each name: registered studies that reported an actual enrolment countActual enrolmentThe number of people a study finished with, recorded after it ran., out of every study registered for that modality. A third figure, where one appears, is how many of those reported an enrolment of zero. The number on the right is the medianMedianThe middle value once everything is lined up in order, which a few unusually large or small entries cannot drag around., and the range beside it is the middle half, the IQRIQRInterquartile range: the stretch covering the middle half of the values, from a quarter of the way up the list to three quarters of the way up..
- 1Botulinum toxin (cosmetic)165 of 186 · 3 at zero13245–300
- 2Calcium hydroxylapatite filler6 of 710162.5–126
- 3Bimatoprost for eyelash growth28 of 28 · 1 at zero79.532.2–285
- 4Poly-L-lactic acid collagen stimulator8 of 1779.547.5–193.2
- 5Hyaluronic acid filler34 of 46 · 1 at zero69.560–104.8
- 6Topical retinoid275 of 343 · 12 at zero6026–269
- 7Topical clascoterone16 of 214618–632.5
- 8Topical hydroquinone / triple combination34 of 513220–56
- 9Monopolar RF skin tightening6 of 93120.5–70
- 10Cryolipolysis14 of 203011.8–49
Median participants per registered trial that reported an actual enrolment; a small median means small studies, not necessarily weak ones. What this measuresMedian number of humans ACTUALLY enrolled, across only those studies that have posted a final actual enrollment; planned or estimated enrollment is deliberately excluded because an intention to enrol is not a person tested, so this median describes the studies that reported, not the whole field, and it says nothing about how long those people were followed. The middle half of actual enrollment counts (25th to 75th percentile, linear interpolation); it shows whether a modality's evidence is a few uniform trials or a mix of tiny case series and large registrational studies, and it is NOT a confidence interval and NOT a statement that any individual trial was adequately powered. How many of this modality's registered studies have posted an ACTUAL enrollment number at all; a low number relative to total registered means most of the enrollment picture is still promises, and it is a reporting-completeness measure, not a quality measure. How many studies posted an actual enrollment of exactly 0, meaning they were withdrawn or terminated before anyone was treated; these are kept in the median rather than filtered out, and a high count is a fact about trials that never happened, not about the treatment.
Methodology →
Results transparency
Under each name: completed registered studies with results postedResults postedWhether the people who ran a study later uploaded its actual outcome numbers to the public registry, which is a separate step from registering the study in the first place., out of that modality's completed studies. The percentage on the right is those two numbers divided.
- 1Cellulite septa release2 of 2100%
- 2Calcium hydroxylapatite filler5 of 683%
- 3Ultrasound lifting & tightening6 of 875%
- 4Topical clascoterone11 of 1573%
- 5Bimatoprost for eyelash growth19 of 2673%
- 6Radiofrequency microneedling15 of 2462%
- 7Topical retinoid111 of 25144%
- 8Botulinum toxin (cosmetic)70 of 16044%
- 9Cryolipolysis5 of 1338%
- 10Poly-L-lactic acid collagen stimulator3 of 838%
Registration is not publication: a low rate means results were not posted to ClinicalTrials.gov, not that the device failed. What this measuresShare of COMPLETED studies that have a results section posted on ClinicalTrials.gov; it measures transparency on the registry specifically, and a study can be fully published in a peer-reviewed journal while still showing no posted results here, so a low rate means 'hard to check on the registry', not 'hidden' or 'failed'. The denominator is beside every rate on purpose — some modalities have only a handful of completed studies, so a single posting moves them a long way up or down this list.
Methodology →
Sponsor concentration
Under each name, in order: the largest lead sponsorLead sponsorThe organisation that takes responsibility for a study, which may be a manufacturer, a hospital, a university or a government body. by name, how many of that modality's studies it registered out of the studies read, and how many distinct lead sponsors the modality has in total. The percentage on the right is the first sponsor's share — its sponsor concentrationSponsor concentrationHow much of a group of studies sits with the single busiest organisation rather than being spread across many..
- 1High-intensity electromagnetic muscle stimulationBTL Industries Ltd. · 4 of 4 · 1100%top 5: 100%
- 2Bimatoprost for eyelash growthAllergan · 20 of 28 · 871%top 5: 89%
- 3Calcium hydroxylapatite fillerMerz North America, Inc. · 5 of 7 · 371%top 5: 100%
- 4Cellulite septa releaseNorthwestern University · 2 of 4 · 350%top 5: 100%
- 5Monopolar RF skin tighteningCLASSYS Inc. · 3 of 9 · 733%top 5: 78%
Sponsor names are the registry's raw lead-sponsor strings — this site does not merge them, so one company spelled two ways counts twice. What this measuresThe five lead sponsors that registered the most studies for this modality, with counts; a single manufacturer holding most of the studies of its own device category is a concentration fact worth knowing, but it is not an accusation -- it often just means one company invented and commercialised the category. Share of fetched studies held by the five largest lead sponsors; high concentration means the evidence base rests on few organisations, which is a fragility fact about the literature, not a verdict on whether the treatment works. The Index publishes a manufacturer alias map, but it covers FDA applicant names and is NOT applied here: these are ClinicalTrials.gov lead-sponsor strings exactly as the registry published them, unnormalised. A company registering under two spellings therefore counts as two sponsors, which can only push a concentration figure DOWN, never up. Concentration is a fragility fact about the literature, not a verdict on a treatment.
Methodology →
No rows in this category.
Under each name, in this order: randomised controlled trialsRandomised controlled trialA study that decides by chance which participants get which treatment, so that the groups being compared start out alike and a difference at the end is easier to pin on the treatment., systematic reviewsSystematic reviewA paper that hunts down every study on one question using a search method it states up front, then summarises what the whole set shows. or meta-analysesMeta-analysisA paper that pools the numbers from several separate studies into a single combined figure., then case reportsCase reportA write-up of one patient, or a small handful, described after the fact — useful as a sign that something can happen, and no guide at all to how often it does.. The large figure on the right is every PubMed record for that treatment; the pill beside it is records carrying either of the first two types — the higher-tier countHigher-tier evidenceThis site's shorthand for the pooled papers and the randomised trials counted together in one search, so a paper carrying both labels is only counted once..
- 1Topical retinoid431 · 90 · 2694,253521
- 2Botulinum toxin (cosmetic)248 · 114 · 2002,201362
- 3Pulsed dye laser118 · 78 · 2871,530196
- 4Ablative / hybrid fractional laser233 · 74 · 1631,485307
- 5Hyaluronic acid filler162 · 41 · 1931,299203
- 6Non-ablative fractional laser188 · 46 · 1141,158234
- 7Topical hydroquinone / triple combination143 · 33 · 891,116176
- 8IPL / broadband light122 · 63 · 861,028185
- 9Laser hair removal56 · 29 · 12674485
- 10Mechanical microneedling59 · 51 · 38620110
No rows in this category.
Counting publications is not a quality measure — the study types are shown so you can see what a headline number is made of. What this measuresCounts of PubMed records by publication type for each modality's fixed, hand-written query. Counting study types is not a quality assessment: a randomised trial can be tiny, unblinded, industry-run and eight weeks long, and it still counts as one RCT here. A modality can have many trials and still lack good long-term outcome data, because almost none of these studies follow patients for years. Rows overlap by design (Clinical Trial includes the randomised trials; reviews and the systematic-review subset intersect), so the rows do not sum to the total and must never be stacked or added. This is a breakdown, not a score, not a grade, and nothing here is multiplied into any ranking. Higher-tier study counts shown next to the raw total. Counting study types is not a quality assessment. A modality can have many trials and still lack good long-term outcome data: most aesthetic studies are small, short, single-centre and often manufacturer-funded, and follow-up past twelve months is rare. A high RCT count means a technique has been tested often, not that it works better, is safer, or lasts longer. The three counts under each row are subsets of the total, and they overlap each other, so they never sum to it and are never stacked. Counts come from the publication-type run of 2026-07-26; its own re-fetch of the unfiltered total is the number shown here.
Methodology →
Under each product: the manufacturer, then the FDA route and the identifier on the record — clearedClearedThe word for a product that came through the 510(k) route, where the FDA agreed it works much like something already on sale. is the word for the 510(k) route, approved for the rest. The figure on the right is whichever measure the column head names.
ProductPapers · modality, last 10 years
Literature counts are for the MODALITY, never the brand — brands sharing a modality legitimately share the number. What this measuresNumber of PubMed records matching a fixed, hand-written title/abstract query for the MODALITY, not the brand. It measures how much has been PUBLISHED about a technique. It is NOT a quality score, NOT an efficacy measure, NOT a count of randomised trials, and NOT comparable across modalities of different ages -- an older technique has had more years to accumulate papers. Query text is stored next to every count so you can run it yourself. Counts are computed per MODALITY, never per brand. Brand-name literature searches reward manufacturers with big marketing departments and punish equally good devices with quieter names. Ranking brands by their own name-hits would be a popularity contest dressed as evidence. Sorting re-orders and re-numbers rows; it never recolors them. The three devices without a confident FDA crosswalk show an em-dash for regulatory fields, with the reason, and sort last on the decision-date view.
Methodology →
- 1ASCE+— not crosswalked2,35379——
- 2Botox CosmeticALLERGAN · Approved BLA1030001,362186Oct 18, 2024+25%
- 3DaxxifyREVANCE THERAPEUTICS, INC. · Approved BLA7611271,362186Aug 11, 2023+25%
- 4DysportIPSEN BIOPHARM LTD · Approved BLA1252741,362186Sep 21, 2023+25%
- 5JeuveauEVOLUS INC · Approved BLA7610851,362186Jul 12, 2019+25%
- 6LetyboHUGEL INC · Approved BLA7612251,362186Feb 29, 2024+25%
- 7XeominMERZ PHARMS · Approved BLA1253601,362186Jun 25, 2026+25%
- 8AkliefGALDERMA LABS LP · Approved NDA2115271,332343Jul 19, 2022+4%
- 9DifferinGALDERMA LABS LP · Approved NDA0203801,332343Dec 27, 2023+4%
- 10RenovaVALEANT PHARMS NORTH · Approved NDA0211081,332343May 25, 2016+4%
- 11Retin-ABAUSCH · Approved NDA0173401,332343May 13, 2016+4%
- 12TazoracALMIRALL · Approved NDA0206001,332343Apr 16, 2018+4%
- 13Belotero BalanceMerz North America, Inc. · Approved P0900161,03346May 3, 2026+20%
- 14Belotero Intense (+) LidocaineMerz North America, Inc. · Approved P2500161,03346Jul 9, 2026+20%
- 15Belotero Volume (+) LidocaineMerz North America, Inc. · Approved P2500201,03346Jun 25, 2026+20%
- 16Juvederm Ultra XCAllergan · Approved P0500471,03346Aug 14, 2025+20%
- 17Juvederm Volbella XCAllergan · Approved P1100331,03346Aug 14, 2025+20%
- 18Juvederm Vollure XCAllergan · Approved P1100331,03346Aug 14, 2025+20%
- 19Juvederm Voluma XCAllergan · Approved P1100331,03346May 8, 2025+20%
- 20Juvederm Volux XCAllergan · Approved P1100331,03346Aug 14, 2025+20%
- 21Profhilo— not crosswalked1,03346—+20%
- 22RHA CollectionTeoxane S.A. · Approved P1700021,03346Jul 2, 2026+20%
- 23Restylane DefyneQ-Med AB · Approved P1400291,03346Apr 14, 2026+20%
- 24Restylane KysseQ-Med AB · Approved P1400291,03346Apr 14, 2026+20%
- 25Restylane LyftQ-Med AB · Approved P0400241,03346Feb 5, 2026+20%
- 26Restylane SilkQ-Med AB · Approved P0400241,03346Dec 23, 2022+20%
- 27Revanesse VersaProllenium Medical Technologies, Inc. · Approved P1600421,03346May 8, 2026+20%
- 28SKINVIVE by JuvedermAllergan · Approved P1100331,03346Jun 11, 2026+20%
- 29AcuPulseLumenis, Ltd. · Cleared K212703940229Oct 19, 2021+43%
- 30Alma HybridAlma Lasers, Inc. · Cleared K251230940229May 21, 2025+43%
- 31CO2RESyneron-Candela Corp · Cleared K181523940229Jul 11, 2018+43%
- 32Halo— not crosswalked940229—+43%
- 33SP DynamisFotona D.O.O. · Cleared K213267940229Sep 8, 2022+43%
- 34SmartXideEl.En S.P.A. · Cleared K240537940229Mar 20, 2024+43%
- 35UltraPulseLumenis Be, Ltd. · Cleared K233301940229Dec 1, 2023+43%
- 36eCO2Lutronic Corporation · Cleared K244060940229Jul 31, 2025+43%
- 37Clear + BrilliantSolta Medical, Inc. · Cleared K223647742128Dec 29, 2022+35%
- 38FraxCandela Corporation · Cleared K212492742128Dec 20, 2021+35%
- 39FraxelSolta Medical · Cleared K242142742128Aug 21, 2024+35%
- 40LaseMDLutronic Global · Cleared K192331742128Nov 12, 2019+35%
- 41CynergyCynosure, Inc. · Cleared K05077961372Jun 27, 2005+13%
- 42VbeamCandela Corporation · Cleared K23099061372Jun 1, 2023+13%
- 43MicroPen EVOEclipse Medcorp, LLC · Cleared K212558564135Nov 24, 2021+29%
- 44Rejuvapen NXTRefine USA, LLC · Cleared K192138564135Apr 9, 2020+29%
- 45SkinPenCrown Aesthetics · Cleared K241400564135Aug 29, 2024+29%
- 46SkinStylusEsthetic Medical, Inc. · Cleared K253002564135Feb 19, 2026+29%
- 47ellacorCytrellis Biosystems, Inc. · Cleared K252752564135Oct 30, 2025+29%
- 48Tri-LumaGALDERMA LABS LP · Approved NDA02111250951Jan 20, 20150%
- 49BBLSciton, Inc · Cleared K03246048843Nov 13, 2003+33%
- 50Harmony XLAlma Lasers, Inc. · Cleared K24304448843Apr 11, 2025+33%
- 51IconCynosure, Inc. · Cleared K14237648843Sep 24, 2014+33%
- 52NordlysCandela Corporation · Cleared K21249248843Dec 20, 2021+33%
- 53Stellar M22Lumenis Be, Ltd. · Cleared K25080948843Apr 16, 2025+33%
- 54RadiesseMerz North America, Inc. · Approved P0500374087Aug 20, 2014+47%
- 55SculptraQ-Med AB · Approved P03005037117Jun 22, 2026+68%
- 56Apogee EliteCynosure, Inc. · Cleared K03403035930Feb 9, 2004−8%
- 57Clarity IILutronic Corporation · Cleared K18356635930Jun 14, 2019−8%
- 58DiolazeInmode MD , Ltd. · Cleared K18071935930Jun 14, 2018−8%
- 59Elite iQCynosure, LLC · Cleared K24039635930Mar 8, 2024−8%
- 60GentleLaseCandela Corp. · Cleared K14073235930Nov 7, 2014−8%
- 61GentleMax ProCandela Corporation · Cleared K20111135930May 26, 2020−8%
- 62LightSheerLumenis, Ltd. · Cleared K17017935930Sep 18, 2017−8%
- 63MotusEl.En S.P.A. · Cleared K24145935930Jun 21, 2024−8%
- 64SopranoAlma Lasers, Inc. · Cleared K23037135930Feb 22, 2023−8%
- 65Splendor XBios S.R.L. · Cleared K24344535930Dec 30, 2024−8%
- 66VectusPalomar Medical Technologies, Inc. · Cleared K12062235930May 23, 2012−8%
- 67AestheFill— not crosswalked33649——
- 68Discovery PicoQuanta System Spa · Cleared K24098330627Jun 6, 2025+34%
- 69PicoCareWontech Co., Ltd. · Cleared K18127230627Jul 31, 2018+34%
- 70PicoPlusLutronic Corporation · Cleared K17370030627Jun 19, 2018+34%
- 71PicoSureCynosure, LLC · Cleared K26157030627Jun 17, 2026+34%
- 72PicoWayCandela Corporation · Cleared K22085330627Oct 13, 2022+34%
- 73enlightenCutera, Inc. · Cleared K18299730627Dec 12, 2018+34%
- 74Agnes RFAgnes Medical Co., Ltd. · Cleared K25021730437Sep 3, 2025+11%
- 75EndyMed IntensifEndymed Medical, Ltd. · Cleared K13050130437Mar 13, 2014+11%
- 76FractoraInvasix , Ltd. · Cleared K10246130437Jun 2, 2011+11%
- 77GeniusCynosure Lutronic Technology Corporation · Cleared K25348430437Jun 29, 2026+11%
- 78INTRAcelJeisys Medical, Inc. · Cleared K18328430437Jan 15, 2020+11%
- 79InfiniLutronic Corporation · Cleared K12148130437Jun 25, 2013+11%
- 80Morpheus8InMode , Ltd. · Cleared K24001730437Jun 13, 2024+11%
- 81PotenzaJeisys Medical, Inc. · Cleared K23121630437Dec 10, 2024+11%
- 82ProfoundCandela Corporation · Cleared K24007030437Jul 1, 2024+11%
- 83Scarlet SRFVIOL Co., Ltd. · Cleared K18087230437Oct 11, 2018+11%
- 84Secret ProIlooda Co,., Ltd. · Cleared K23337430437Dec 14, 2023+11%
- 85Secret RFIlooda Co,., Ltd. · Cleared K18235530437Sep 6, 2019+11%
- 86Sylfirm XVIOL Co., Ltd. · Cleared K21361230437Jun 23, 2022+11%
- 87Venus VivaVenus Concept USA, Inc. · Cleared K20116430437Jun 26, 2020+11%
- 88VirtueRFShenB Co., Ltd. · Cleared K21156230437Nov 23, 2021+11%
- 89VivaceShenB Co., Ltd. · Cleared K19307030437Apr 26, 2021+11%
- 90TempSureCynosure, LLC · Cleared K2232922939Nov 23, 2022+57%
- 91ThermageSolta Medical · Cleared K1737592939Jan 8, 2018+57%
- 92VolnewmerClassys, Inc. · Cleared K2402482939Apr 29, 2024+57%
- 93SofwaveSofwave Medical, Ltd. · Cleared K25014626116Apr 18, 2025+73%
- 94UltherapyUlthera, Inc. · Cleared K26061826116May 21, 2026+73%
- 95CoolSculptingZeltiq Aesthetics, Inc. · Cleared K19356619920Jan 21, 2020+75%
- 96CoolSculpting EliteZeltiq Aesthetics, Inc. (Acquired by Allergan Aesthetics · Cleared K23373219920Sep 12, 2024+75%
- 97AccentAlma Lasers, Inc. · Cleared K1011471740Jan 21, 2011+38%
- 98ExilisBTL Industries, Inc. · Cleared K1631761740Jan 12, 2017+38%
- 99NuEra TightBios S.R.L. · Cleared K2307551740Oct 30, 2023+38%
- 100VelaShapeSyneron Medical, Ltd. · Cleared K1225791740Sep 13, 2012+38%
- 101Venus LegacyVenus Concept USA, Inc. · Cleared K1915281740Sep 6, 2019+38%
- 102truSculptCutera, Inc. · Cleared K1807091740Jun 6, 2018+38%
- 103truSculpt iDCutera, Inc. · Cleared K2231101740Nov 3, 2022+38%
- 104Rejuran— not crosswalked12116——
- 105CellREDM— not crosswalked112106——
- 106Elravie Re2O— not crosswalked112106——
- 107Juveacell— not crosswalked112106——
- 108WinleviSUN PHARM · Approved NDA2134338821Mar 18, 2022+17%
- 109HydraFacial— not crosswalked739—−78%
- 110CoolToneZimmer Medizinsysteme GmbH · Cleared K253408614Jan 16, 2026−38%
- 111Emsculpt NEO— not crosswalked614—−38%
- 112LatisseABBVIE · Approved NDA0223695228Aug 26, 20210%
- 113Emerald LaserErchonia Corporation · Cleared K192544490Jan 13, 2020−25%
- 114SculpSureCynosure · Cleared K182741490Jan 3, 2019−25%
- 115Venus BlissVenus Concept USA, Inc. · Cleared K220592490Apr 27, 2022−25%
- 116ZeronaErchonia Corporation · Cleared K243811490Jan 10, 2025−25%
- 117AveliRevelle Aesthetics, Inc. · Cleared K232153454Aug 18, 2023−80%
- 118CellfinaUlthera, Inc. · Cleared K192185454Oct 9, 2019−80%
- 119CellulazeCynosure, Inc. · Cleared K123407454Mar 29, 2013−80%
- 120AccureAccure Acne, Inc. · Cleared K242035405Oct 11, 2024+14%
- 121AviClearCutera, Inc. · Cleared K251149405Jul 11, 2025+14%
- 122AerolaseAerolase Medical Lasers, LLC · Cleared K120235——Sep 17, 2012—
- 123BLU-USun Pharmaceutical Industries, Inc. · Cleared K241358——Jun 13, 2024—
- 124BellafillTiger Aesthetics Medical, LLC · Approved P020012——May 12, 2026—
- 125CellumaBiophotas, Inc. · Cleared K232977——Nov 21, 2023—
- 126Ellansé— not crosswalked————
- 127Hollywood SpectraLutronic Corporation · Cleared K213569——Feb 4, 2022—
- 128Hylenex recombinantHALOZYME THERAP · Approved BLA021859——Jan 12, 2024—
- 129KybellaABBVIE · Approved NDA206333——Oct 5, 2022—
- 130LightStimLed Intellectual Properties, LLC · Cleared K212771——Jan 26, 2022—
- 131OmniluxGlobalmed Technologies · Cleared K210948——Jun 24, 2021—
- 132RevLiteCynosure, Inc. · Cleared K133254——Mar 5, 2014—
- 133RogaineKENVUE BRANDS · Approved NDA019501——Jan 14, 2026—
- 134TRI-BEAMJeisys Medical Incorporated · Cleared K251464——Oct 3, 2025—
- 135UltraShapeSyneron Medical, Ltd. · Cleared K170370——May 15, 2017—
- 136truSculpt flexJohari Digital Healthcare Limited · Cleared K212866——Dec 3, 2022—
No rows in this category.
| Device | Manufacturer | Regulatory status | Papers (modality, last 10 years) | Registered studies (modality, all time) | Latest FDA decision |
|---|---|---|---|---|---|
| ASCE+ | — | not crosswalked | 2,353 | 79 | — |
| Botox Cosmetic | ALLERGAN | Approved BLA103000 | 1,362 | 186 | 2024-10-18 |
| Daxxify | REVANCE THERAPEUTICS, INC. | Approved BLA761127 | 1,362 | 186 | 2023-08-11 |
| Dysport | IPSEN BIOPHARM LTD | Approved BLA125274 | 1,362 | 186 | 2023-09-21 |
| Jeuveau | EVOLUS INC | Approved BLA761085 | 1,362 | 186 | 2019-07-12 |
| Letybo | HUGEL INC | Approved BLA761225 | 1,362 | 186 | 2024-02-29 |
| Xeomin | MERZ PHARMS | Approved BLA125360 | 1,362 | 186 | 2026-06-25 |
| Aklief | GALDERMA LABS LP | Approved NDA211527 | 1,332 | 343 | 2022-07-19 |
| Differin | GALDERMA LABS LP | Approved NDA020380 | 1,332 | 343 | 2023-12-27 |
| Renova | VALEANT PHARMS NORTH | Approved NDA021108 | 1,332 | 343 | 2016-05-25 |
| Retin-A | BAUSCH | Approved NDA017340 | 1,332 | 343 | 2016-05-13 |
| Tazorac | ALMIRALL | Approved NDA020600 | 1,332 | 343 | 2018-04-16 |
| Belotero Balance | Merz North America, Inc. | Approved P090016 | 1,033 | 46 | 2026-05-03 |
| Belotero Intense (+) Lidocaine | Merz North America, Inc. | Approved P250016 | 1,033 | 46 | 2026-07-09 |
| Belotero Volume (+) Lidocaine | Merz North America, Inc. | Approved P250020 | 1,033 | 46 | 2026-06-25 |
| Juvederm Ultra XC | Allergan | Approved P050047 | 1,033 | 46 | 2025-08-14 |
| Juvederm Volbella XC | Allergan | Approved P110033 | 1,033 | 46 | 2025-08-14 |
| Juvederm Vollure XC | Allergan | Approved P110033 | 1,033 | 46 | 2025-08-14 |
| Juvederm Voluma XC | Allergan | Approved P110033 | 1,033 | 46 | 2025-05-08 |
| Juvederm Volux XC | Allergan | Approved P110033 | 1,033 | 46 | 2025-08-14 |
| Profhilo | — | not crosswalked | 1,033 | 46 | — |
| RHA Collection | Teoxane S.A. | Approved P170002 | 1,033 | 46 | 2026-07-02 |
| Restylane Defyne | Q-Med AB | Approved P140029 | 1,033 | 46 | 2026-04-14 |
| Restylane Kysse | Q-Med AB | Approved P140029 | 1,033 | 46 | 2026-04-14 |
| Restylane Lyft | Q-Med AB | Approved P040024 | 1,033 | 46 | 2026-02-05 |
| Restylane Silk | Q-Med AB | Approved P040024 | 1,033 | 46 | 2022-12-23 |
| Revanesse Versa | Prollenium Medical Technologies, Inc. | Approved P160042 | 1,033 | 46 | 2026-05-08 |
| SKINVIVE by Juvederm | Allergan | Approved P110033 | 1,033 | 46 | 2026-06-11 |
| AcuPulse | Lumenis, Ltd. | Cleared K212703 | 940 | 229 | 2021-10-19 |
| Alma Hybrid | Alma Lasers, Inc. | Cleared K251230 | 940 | 229 | 2025-05-21 |
| CO2RE | Syneron-Candela Corp | Cleared K181523 | 940 | 229 | 2018-07-11 |
| Halo | — | not crosswalked | 940 | 229 | — |
| SP Dynamis | Fotona D.O.O. | Cleared K213267 | 940 | 229 | 2022-09-08 |
| SmartXide | El.En S.P.A. | Cleared K240537 | 940 | 229 | 2024-03-20 |
| UltraPulse | Lumenis Be, Ltd. | Cleared K233301 | 940 | 229 | 2023-12-01 |
| eCO2 | Lutronic Corporation | Cleared K244060 | 940 | 229 | 2025-07-31 |
| Clear + Brilliant | Solta Medical, Inc. | Cleared K223647 | 742 | 128 | 2022-12-29 |
| Frax | Candela Corporation | Cleared K212492 | 742 | 128 | 2021-12-20 |
| Fraxel | Solta Medical | Cleared K242142 | 742 | 128 | 2024-08-21 |
| LaseMD | Lutronic Global | Cleared K192331 | 742 | 128 | 2019-11-12 |
| Cynergy | Cynosure, Inc. | Cleared K050779 | 613 | 72 | 2005-06-27 |
| Vbeam | Candela Corporation | Cleared K230990 | 613 | 72 | 2023-06-01 |
| MicroPen EVO | Eclipse Medcorp, LLC | Cleared K212558 | 564 | 135 | 2021-11-24 |
| Rejuvapen NXT | Refine USA, LLC | Cleared K192138 | 564 | 135 | 2020-04-09 |
| SkinPen | Crown Aesthetics | Cleared K241400 | 564 | 135 | 2024-08-29 |
| SkinStylus | Esthetic Medical, Inc. | Cleared K253002 | 564 | 135 | 2026-02-19 |
| ellacor | Cytrellis Biosystems, Inc. | Cleared K252752 | 564 | 135 | 2025-10-30 |
| Tri-Luma | GALDERMA LABS LP | Approved NDA021112 | 509 | 51 | 2015-01-20 |
| BBL | Sciton, Inc | Cleared K032460 | 488 | 43 | 2003-11-13 |
| Harmony XL | Alma Lasers, Inc. | Cleared K243044 | 488 | 43 | 2025-04-11 |
| Icon | Cynosure, Inc. | Cleared K142376 | 488 | 43 | 2014-09-24 |
| Nordlys | Candela Corporation | Cleared K212492 | 488 | 43 | 2021-12-20 |
| Stellar M22 | Lumenis Be, Ltd. | Cleared K250809 | 488 | 43 | 2025-04-16 |
| Radiesse | Merz North America, Inc. | Approved P050037 | 408 | 7 | 2014-08-20 |
| Sculptra | Q-Med AB | Approved P030050 | 371 | 17 | 2026-06-22 |
| Apogee Elite | Cynosure, Inc. | Cleared K034030 | 359 | 30 | 2004-02-09 |
| Clarity II | Lutronic Corporation | Cleared K183566 | 359 | 30 | 2019-06-14 |
| Diolaze | Inmode MD , Ltd. | Cleared K180719 | 359 | 30 | 2018-06-14 |
| Elite iQ | Cynosure, LLC | Cleared K240396 | 359 | 30 | 2024-03-08 |
| GentleLase | Candela Corp. | Cleared K140732 | 359 | 30 | 2014-11-07 |
| GentleMax Pro | Candela Corporation | Cleared K201111 | 359 | 30 | 2020-05-26 |
| LightSheer | Lumenis, Ltd. | Cleared K170179 | 359 | 30 | 2017-09-18 |
| Motus | El.En S.P.A. | Cleared K241459 | 359 | 30 | 2024-06-21 |
| Soprano | Alma Lasers, Inc. | Cleared K230371 | 359 | 30 | 2023-02-22 |
| Splendor X | Bios S.R.L. | Cleared K243445 | 359 | 30 | 2024-12-30 |
| Vectus | Palomar Medical Technologies, Inc. | Cleared K120622 | 359 | 30 | 2012-05-23 |
| AestheFill | — | not crosswalked | 336 | 49 | — |
| Discovery Pico | Quanta System Spa | Cleared K240983 | 306 | 27 | 2025-06-06 |
| PicoCare | Wontech Co., Ltd. | Cleared K181272 | 306 | 27 | 2018-07-31 |
| PicoPlus | Lutronic Corporation | Cleared K173700 | 306 | 27 | 2018-06-19 |
| PicoSure | Cynosure, LLC | Cleared K261570 | 306 | 27 | 2026-06-17 |
| PicoWay | Candela Corporation | Cleared K220853 | 306 | 27 | 2022-10-13 |
| enlighten | Cutera, Inc. | Cleared K182997 | 306 | 27 | 2018-12-12 |
| Agnes RF | Agnes Medical Co., Ltd. | Cleared K250217 | 304 | 37 | 2025-09-03 |
| EndyMed Intensif | Endymed Medical, Ltd. | Cleared K130501 | 304 | 37 | 2014-03-13 |
| Fractora | Invasix , Ltd. | Cleared K102461 | 304 | 37 | 2011-06-02 |
| Genius | Cynosure Lutronic Technology Corporation | Cleared K253484 | 304 | 37 | 2026-06-29 |
| INTRAcel | Jeisys Medical, Inc. | Cleared K183284 | 304 | 37 | 2020-01-15 |
| Infini | Lutronic Corporation | Cleared K121481 | 304 | 37 | 2013-06-25 |
| Morpheus8 | InMode , Ltd. | Cleared K240017 | 304 | 37 | 2024-06-13 |
| Potenza | Jeisys Medical, Inc. | Cleared K231216 | 304 | 37 | 2024-12-10 |
| Profound | Candela Corporation | Cleared K240070 | 304 | 37 | 2024-07-01 |
| Scarlet SRF | VIOL Co., Ltd. | Cleared K180872 | 304 | 37 | 2018-10-11 |
| Secret Pro | Ilooda Co,., Ltd. | Cleared K233374 | 304 | 37 | 2023-12-14 |
| Secret RF | Ilooda Co,., Ltd. | Cleared K182355 | 304 | 37 | 2019-09-06 |
| Sylfirm X | VIOL Co., Ltd. | Cleared K213612 | 304 | 37 | 2022-06-23 |
| Venus Viva | Venus Concept USA, Inc. | Cleared K201164 | 304 | 37 | 2020-06-26 |
| VirtueRF | ShenB Co., Ltd. | Cleared K211562 | 304 | 37 | 2021-11-23 |
| Vivace | ShenB Co., Ltd. | Cleared K193070 | 304 | 37 | 2021-04-26 |
| TempSure | Cynosure, LLC | Cleared K223292 | 293 | 9 | 2022-11-23 |
| Thermage | Solta Medical | Cleared K173759 | 293 | 9 | 2018-01-08 |
| Volnewmer | Classys, Inc. | Cleared K240248 | 293 | 9 | 2024-04-29 |
| Sofwave | Sofwave Medical, Ltd. | Cleared K250146 | 261 | 16 | 2025-04-18 |
| Ultherapy | Ulthera, Inc. | Cleared K260618 | 261 | 16 | 2026-05-21 |
| CoolSculpting | Zeltiq Aesthetics, Inc. | Cleared K193566 | 199 | 20 | 2020-01-21 |
| CoolSculpting Elite | Zeltiq Aesthetics, Inc. (Acquired by Allergan Aesthetics | Cleared K233732 | 199 | 20 | 2024-09-12 |
| Accent | Alma Lasers, Inc. | Cleared K101147 | 174 | 0 | 2011-01-21 |
| Exilis | BTL Industries, Inc. | Cleared K163176 | 174 | 0 | 2017-01-12 |
| NuEra Tight | Bios S.R.L. | Cleared K230755 | 174 | 0 | 2023-10-30 |
| VelaShape | Syneron Medical, Ltd. | Cleared K122579 | 174 | 0 | 2012-09-13 |
| Venus Legacy | Venus Concept USA, Inc. | Cleared K191528 | 174 | 0 | 2019-09-06 |
| truSculpt | Cutera, Inc. | Cleared K180709 | 174 | 0 | 2018-06-06 |
| truSculpt iD | Cutera, Inc. | Cleared K223110 | 174 | 0 | 2022-11-03 |
| Rejuran | — | not crosswalked | 121 | 16 | — |
| CellREDM | — | not crosswalked | 112 | 106 | — |
| Elravie Re2O | — | not crosswalked | 112 | 106 | — |
| Juveacell | — | not crosswalked | 112 | 106 | — |
| Winlevi | SUN PHARM | Approved NDA213433 | 88 | 21 | 2022-03-18 |
| HydraFacial | — | not crosswalked | 73 | 9 | — |
| CoolTone | Zimmer Medizinsysteme GmbH | Cleared K253408 | 61 | 4 | 2026-01-16 |
| Emsculpt NEO | — | not crosswalked | 61 | 4 | — |
| Latisse | ABBVIE | Approved NDA022369 | 52 | 28 | 2021-08-26 |
| Emerald Laser | Erchonia Corporation | Cleared K192544 | 49 | 0 | 2020-01-13 |
| SculpSure | Cynosure | Cleared K182741 | 49 | 0 | 2019-01-03 |
| Venus Bliss | Venus Concept USA, Inc. | Cleared K220592 | 49 | 0 | 2022-04-27 |
| Zerona | Erchonia Corporation | Cleared K243811 | 49 | 0 | 2025-01-10 |
| Aveli | Revelle Aesthetics, Inc. | Cleared K232153 | 45 | 4 | 2023-08-18 |
| Cellfina | Ulthera, Inc. | Cleared K192185 | 45 | 4 | 2019-10-09 |
| Cellulaze | Cynosure, Inc. | Cleared K123407 | 45 | 4 | 2013-03-29 |
| Accure | Accure Acne, Inc. | Cleared K242035 | 40 | 5 | 2024-10-11 |
| AviClear | Cutera, Inc. | Cleared K251149 | 40 | 5 | 2025-07-11 |
| Aerolase | Aerolase Medical Lasers, LLC | Cleared K120235 | — | — | 2012-09-17 |
| BLU-U | Sun Pharmaceutical Industries, Inc. | Cleared K241358 | — | — | 2024-06-13 |
| Bellafill | Tiger Aesthetics Medical, LLC | Approved P020012 | — | — | 2026-05-12 |
| Celluma | Biophotas, Inc. | Cleared K232977 | — | — | 2023-11-21 |
| Ellansé | — | not crosswalked | — | — | — |
| Hollywood Spectra | Lutronic Corporation | Cleared K213569 | — | — | 2022-02-04 |
| Hylenex recombinant | HALOZYME THERAP | Approved BLA021859 | — | — | 2024-01-12 |
| Kybella | ABBVIE | Approved NDA206333 | — | — | 2022-10-05 |
| LightStim | Led Intellectual Properties, LLC | Cleared K212771 | — | — | 2022-01-26 |
| Omnilux | Globalmed Technologies | Cleared K210948 | — | — | 2021-06-24 |
| RevLite | Cynosure, Inc. | Cleared K133254 | — | — | 2014-03-05 |
| Rogaine | KENVUE BRANDS | Approved NDA019501 | — | — | 2026-01-14 |
| TRI-BEAM | Jeisys Medical Incorporated | Cleared K251464 | — | — | 2025-10-03 |
| UltraShape | Syneron Medical, Ltd. | Cleared K170370 | — | — | 2017-05-15 |
| truSculpt flex | Johari Digital Healthcare Limited | Cleared K212866 | — | — | 2022-12-03 |
Narrow (unambiguously aesthetic) codes
clearances per month
| Lasers & Light | Body Contouring | Skin & Topicals | RF & Microneedling | Total | |
|---|---|---|---|---|---|
| Aug | 6 | 0 | 0 | 2 | 8 |
| Sep | 6 | 0 | 0 | 1 | 7 |
| Oct | 13 | 0 | 0 | 3 | 16 |
| Nov | 6 | 0 | 0 | 0 | 6 |
| Dec | 11 | 3 | 0 | 0 | 14 |
| Jan | 4 | 0 | 0 | 1 | 5 |
| Feb | 3 | 1 | 0 | 1 | 5 |
| Mar | 7 | 0 | 0 | 2 | 9 |
| Apr | 2 | 1 | 0 | 1 | 4 |
| May | 4 | 2 | 0 | 1 | 7 |
| Jun | 9 | 0 | 0 | 0 | 9 |
510(k) decisions per month in unambiguously aesthetic codes — filing tempo, not adoption. What this measuresCount of FDA 510(k) clearance DECISIONS per month whose product code is on the Dalphene aesthetic allowlist. A clearance is not an approval, not efficacy, not safety, not sales; manufacturers file multiple 510(k)s per platform, so this tracks filing activity. Zeros are real: the window's clearance list is complete, so an empty month is an empty month. The first month (2025-07) and last month (2026-07) cover only part of a calendar month because the window is a rolling 365 days ending 2026-07-25. The two partial edge months are excluded from the chart so they cannot read as a dip; they are in the data table, marked partial. Legend values are each category's total over the 11 full months.
Methodology →
All tracked codes — includes broad, mixed-use codes (GEX, GEI, NGX)
clearances per month
| Lasers & Light | Body Contouring | Skin & Topicals | RF & Microneedling | Total | |
|---|---|---|---|---|---|
| Aug | 10 | 1 | 0 | 8 | 19 |
| Sep | 12 | 0 | 0 | 6 | 18 |
| Oct | 25 | 0 | 0 | 11 | 36 |
| Nov | 17 | 1 | 0 | 4 | 22 |
| Dec | 16 | 4 | 0 | 1 | 21 |
| Jan | 8 | 1 | 0 | 7 | 16 |
| Feb | 9 | 1 | 0 | 4 | 14 |
| Mar | 14 | 1 | 0 | 7 | 22 |
| Apr | 7 | 2 | 0 | 6 | 15 |
| May | 12 | 2 | 0 | 5 | 19 |
| Jun | 12 | 0 | 0 | 9 | 21 |
All tracked codes, including broad ones that also carry non-aesthetic devices — an overcount by construction. What this measuresCount of FDA 510(k) clearance DECISIONS per month whose product code is on the Dalphene aesthetic allowlist. A clearance is not an approval, not efficacy, not safety, not sales; manufacturers file multiple 510(k)s per platform, so this tracks filing activity. Zeros are real: the window's clearance list is complete, so an empty month is an empty month. by_category includes rows from broad-mixed product codes (GEX, GEI, NGX) that also carry non-aesthetic devices. Default charts to narrow_by_category; the broad view is a labelled opt-in — same rule as clearances.json. The first month (2025-07) and last month (2026-07) cover only part of a calendar month because the window is a rolling 365 days ending 2026-07-25.
Methodology →
Under each name is the category it sits in. On the right: registered studiesRegistered studyA study written into the public registry, which records that someone planned or ran it and says nothing about whether it finished or what it found. of all time on ClinicalTrials.govClinicalTrials.govThe United States public registry where the people running a study record it before or during the study, which is where this site's study counts come from., then the pill is how many of them were recruiting on the run date.
- 1Topical retinoidSkin & Topicals34314
- 2Ablative / hybrid fractional laserLasers & Light22913
- 3Botulinum toxin (cosmetic)Injectables1864
- 4Mechanical microneedlingRF & Microneedling13513
- 5Non-ablative fractional laserLasers & Light12810
- 6Human acellular dermal matrix (ECM) boosterInjectables10612
- 7Exosome / extracellular-vesicle preparationInjectables7918
- 8Pulsed dye laserLasers & Light723
- 9Topical hydroquinone / triple combinationSkin & Topicals514
- 10PDLLA / PLLA collagen biostimulatorInjectables496
No rows in this category.
Registered studies naming the treatment — registration is not completion, publication or result. What this measuresNumber of studies registered on ClinicalTrials.gov matching a fixed intervention query ANDed with a cosmetic/dermatologic condition query. Registration is not completion, not publication, and not a result. Counts include studies of any status, size or sponsor. The recruiting count is a snapshot on the run date and will change. 2 of the 29 modalities returned a genuine fetched zero (Non-invasive laser lipolysis, RF body contouring): the query ran and matched nothing, which is not the same as a missing value.
Methodology →
Each row: the FDA decision dateDecision dateThe date the FDA recorded its decision on a submission, which is the date this site counts a clearance under., the device name as the record spells it, then the applicant and category. The mono-spaced pill is the K-number, and it opens that record on openFDA. A row tagged “Broad code” came from GEX, GEI or NGX, which also carry non-aesthetic devices.
- Capenergy C Equipments RF C200 and C400 DrakarianCapenergy Medical S.L. · RF & Microneedling
- ChromixTermosalud S.L. · Lasers & Light
- THUNDERBEAT 5 mm, 45 cm, Front-actuated Grip Type S (TB-0545FCS); THUNDERBEAT 5 mm, 35 cm, Front-actuated Grip Type S (TB-0535FCS); THUNDERBEAT 5 mm, 20 cm, Front-actuated Grip Type S (TB-0520FCS)Olympus Medical Systems Corp. · RF & Microneedling
- LED Light Therapy Masks (LED Face Mask Pro FAC08NA, LED Chest Mask Pro FAC09NA)Guangdong Newdermo Biotech Co., Ltd. · Lasers & Light
- LUTRONIC GENIUSCynosure Lutronic Technology Corporation · RF & Microneedling
- Irrigation Tubing Bipolar Cord SetNew Deantronics Taiwan , Ltd. · RF & Microneedling
- Laser Hair Growth Devices (HR-H1, HR-H2, HR-H3, HR-H4, HR-H5, HR-H6, HR-H7, HR-H8, HR-H9, HR-H10, HR-I1, HR-I2, HR-I3, HR-I4, HR-I5)Ziree Co., Ltd. · Lasers & Light
- Hemolase Fiber (Hemo-R-0.40-2.5/Hemo-R-0.60-2.5/Hemo-R-0.40-1.8/Hemo-R-0.60-1.8)Micro-Energy Medical Technology Co., Ltd. · Lasers & Light
- LED Light Therapy Mask (K9C-TK, K9C-K, K9P-YK, K9P-K, FM-03BK, FM-09K)Guangdong Newdermo Biotech Co., Ltd. · Lasers & Light
- Remanufactured LigaSure XP Maryland Jaw Sealer/Divider Without Nano-coatingStryker Sustainability Solutions · RF & Microneedling
- PICOSURE WORKSTATIONCynosure, LLC · Lasers & Light
- CoolSeal Generator® (CSL-200-90)Hologic, Inc. · RF & Microneedling
- NEUROMARK System (NMK00301)Neurent Medical , Ltd. · RF & Microneedling
- Laser Hair Growth Device (F21151, F21152, F21153, F21154, F21155, F21156, F21157, F21158, F21159)Zdeer Technology (Henan) Co., Ltd. · Lasers & Light
- LED Neck Beauty Mask (ZLD-66A,ZLD-90E,ZLD-130,ZLD-180H)Shenzhen Kaiyan Medical Equipment Co., Ltd. · Lasers & Light
- Laser Hair Growth System (Laser Cap 128, Laser Helmet 272, Laser Helmet 352, Laser Helmet 552, Laser Helmet 500)Hubei Yjt Technology Co.,Ltd · Lasers & Light
- Intense Pulsed Light Therapy DeviceSanhe LEFIS Electronics Co., Ltd. · Lasers & Light
- LAP-iX2NSejong Medical Co., Ltd. · RF & Microneedling
- OsteoCool RF Ablation System; OsteoCool 2.0 RF Ablation SystemMedtronic Sofamor Danek USA, Inc. · RF & Microneedling
- Alma TED+ SystemAlma Lasers, Inc. · Lasers & Light
- LumiGlam Laser System (SHE-LSP601-3)Beijing Sano Laser S&T Development Co.,Ltd · Lasers & Light
- CurrentBody Skin LED Multi Light Therapy Mask (MK-110D)The Beauty Tech Group, Ltd. · Lasers & Light
- Veineo System (00MEDRF4000TCUS 05CR45iT 06Pedal1St)F Care Systems USA, LLC · RF & Microneedling
- MILAN SystemLumenis Be, Ltd. · RF & Microneedling
- ENTire IRE SystemEntire Medical , Ltd. · RF & Microneedling
- LASEmaR 1500Eufoton S.R.L. · Lasers & Light
- LUNE PureHygieneEnamel Pure · Lasers & Light
- VIVA combo RF SystemStarmed Co., Ltd. · RF & Microneedling
- Ice Cooling IPL Hair Removal Device (UI06S PR, UI06S PN, UI06S WH, UI06S PRU, UI06S PNU, UI06S WHU)Shenzhen Ulike Smart Electronics Co., Ltd. · Lasers & Light
- Ulthera® SystemUlthera, Inc. · Body Contouring
- Boston 2910 (Boston 2910)Boston Aesthetics, Inc. · Lasers & Light
- IPL Hair Removal Device (FL-B505AG, FL-B505AP, FL-B505AM, FL-B507AG, FL-B507AP, FL-B507AM, FL-B508AG, FL-B508AP, FL-B508AM, FL-B509AG, FL-B509AP, FL-B509AM, FL-B510G, FL-B510P, FL-B510M, FL-B511G, FL-B511P, FL-B511M, FL-B512AG, FL-B512AP, FL-B512AM, FL-B513AG, FL-B513AP, FL-B513AM)Shenzhen Xiazhifeng Electronic Co., Ltd. · Lasers & Light
- LAGIS Endoscopic Instruments- Scissors (EI-330S EI-330S-T EI-330MS EI-330MS-T)Lagis Enterprise Co., Ltd. · RF & Microneedling
- RhinAer+ StylusAerin Medical, Inc. · RF & Microneedling
- MOSES RaydarBoston Scientific Corporation · Lasers & Light
- Automatic Micro Needle System (CODE-X)Woorhi Mechatronics Co., Ltd. · RF & Microneedling
- myLEDmask 2 (MJ-144)Light Tree Ventures Europe B.V. · Lasers & Light
- PICO SHINING (PICO-K; PICOFY)Speclipse, Inc. · Lasers & Light
- CO2 Laser Machine (Monica-I,Monica-II)Nanjing Bestview Laser S&T Co., Ltd. · Lasers & Light
- Ice Cooling IPL Hair Removal Device (UI20S DB, UI20S RE, UI20S PW, UI20S GP, UI20S GR, UI20S BK)Shenzhen Ulike Smart Electronics Co., Ltd. · Lasers & Light
- Sculpt LED Belt (HY-150A/HY-150B/HY-200A/HY-200B/HY-420A/HY-200D/HY-200C)Shenzhen Kaiyan Medical Equipment Co., Ltd. · Body Contouring
- Q-Switched Nd: YAG Laser SystemsShanghai Apolo Medical Technology Co., Ltd. · Lasers & Light
- Leaseir MHR Xcell (console) (MHR-100b); Handpiece: Dual (810-b and Blend-b); Handpiece: Quad (810-b and Blend-b)Leaseir Technologies, Slu · Lasers & Light
- YellowStarAsclepion Laser Technologies GmbH · Lasers & Light
No rows in this category.
510(k) decisions in the aesthetic product codes we track — filings, not sales, safety or efficacy. What this measuresCount of FDA 510(k) clearance decisions whose product code is on the Dalphene aesthetic allowlist. A clearance means FDA agreed the device is substantially equivalent to a legally marketed predicate. It is NOT an approval, NOT a measure of efficacy, NOT a measure of safety, and NOT a measure of sales. Manufacturers file multiple 510(k)s for the same platform (new applicators, new indications, new software), so clearance counts track filing activity, not the number of distinct products. Rows with code_breadth = 'broad_mixed' come from product codes (GEX, GEI, NGX) that also carry non-aesthetic devices. They are included because most real aesthetic platforms are cleared under them -- but they also pull in things like general-surgery electrosurgical generators and lithotripsy lasers that no med spa would ever buy. These rows have NOT been individually vetted as aesthetic. The UI should default to the narrow-code counts and offer the broad view as an explicit, labelled opt-in. Any chart that mixes them must say so on the chart. 138 of the 231 clearances in this 365-day window come from the broad codes and are tagged “Broad code” rather than quietly deleted.
Methodology →
Not here: adverse-event data, and sales, usage or market share — none of it exists in a source we would publish. What this measuresNo adverse-event data: MAUDE device adverse events and FAERS drug adverse events were never fetched, are not stored and will not be published here. Adverse-event counts are reporting artifacts, not risk rates. There is no denominator (units sold / procedures performed), reporting is voluntary and duplicated, and a report is not evidence of causation. Publishing them next to brand names would be actively misleading. The Dalphene Index does not fetch, store or display them. No sales, revenue, install-base or usage figures: nobody publishes them, so nothing here is a proxy for them. Filing counts, publication counts and trial registrations are the honest proxies, and each is labelled as such. 2026 is a partial year and the two edge months of the clearance window are partial months: every chart draws them dimmed or excludes them with a note — never extrapolated. 3 seed products could not be matched to an FDA record and carry no clearance date, K-number or manufacturer anywhere on this site (Halo: no confident 510(k) match; regulatory fields null; Emsculpt NEO: no confident 510(k) match; regulatory fields null; HydraFacial: no confident 510(k) match; regulatory fields null). Each shows an em-dash with the reason, never a guess. 2026 is drawn as a partial year on both hero tabs — dimmed, never extrapolated. FDA publishes decisions to its releasable database on a lag, so the newest days always undercount. Evidence-quality metrics describe REGISTERED studies on ClinicalTrials.gov. Device studies are systematically under-registered relative to drugs, so much of the aesthetic evidence base sits in journals with no registry record at all and is invisible to every number in that section. Publication type is assigned by NLM indexers, not by any assessment of quality: a landmark trial and a badly run one are both one randomised controlled trial here. Delta chips on device rows compare modality-level PubMed volume 2025 vs 2024 — a research-attention signal, not a product metric. Skin & Topicals device codes recorded zero 510(k) decisions in every month of the window — a real fetched zero, kept in the tables. 7 of these 44 decisions landed in the last 30 days; FDA publishes to its releasable database on a lag, so the current month always undercounts.
Methodology →